Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab ...

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

IL-17 inhibitors secukinumab and brodalumab demonstrate similar efficacy in patients with psoriasis for up to a year after dose spacing, according to a retrospective cohort study.

Objectives To investigate patient characteristics predictive of response to secukinumab in patients with psoriatic arthritis (PsA) with axial manifestations.Methods In a post-hoc analysis from the ...